{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:23:53Z","timestamp":1794565433853,"version":"4.9.1"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007834","name":"Ningbo Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["2023J021"],"award-info":[{"award-number":["2023J021"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007834","name":"Ningbo Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["2023J386"],"award-info":[{"award-number":["2023J386"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LHDMY25H030003"],"award-info":[{"award-number":["LHDMY25H030003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY24H160002"],"award-info":[{"award-number":["LY24H160002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQN25H290002"],"award-info":[{"award-number":["LQN25H290002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82405106"],"award-info":[{"award-number":["82405106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571585"],"award-info":[{"award-number":["32571585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biomaterials.2026.124247","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:57:38Z","timestamp":1777841858000},"page":"124247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in multi-dimensional targeting probes for precision medicine of breast cancer"],"prefix":"10.1016","volume":"334","author":[{"given":"Pengli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3378-4860","authenticated-orcid":false,"given":"Manxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2464-3890","authenticated-orcid":false,"given":"Sijia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3195-5155","authenticated-orcid":false,"given":"Tianxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiguo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8686-0890","authenticated-orcid":false,"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"2025, CA Cancer J Clin"},{"key":"10.1016\/j.biomaterials.2026.124247_bib2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023","volume":"406","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biomaterials.2026.124247_bib3","article-title":"PIK3CA mutations and first-line outcomes in endocrine-resistant HR+\/HER2- metastatic breast cancer: a multicentric real-world study","volume":"234","author":"Dieci","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib4","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/noaf018","article-title":"Phase II trial of brain MRI surveillance in stage IV breast cancer","volume":"27","author":"Ahmed","year":"2025","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jbi\/wbaf009","article-title":"Breast arterial calcifications on mammography: a review of the literature","volume":"7","author":"Rossi","year":"2025","journal-title":"J. Breast Imaging"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40477-022-00755-3","article-title":"Diagnostic performance of mammography and ultrasound in breast cancer: a systematic review and meta-analysis","volume":"26","author":"Tadesse","year":"2023","journal-title":"J. Ultrasound"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11912-023-01372-x","article-title":"Breast MRI: clinical indications, recommendations, and future applications in breast cancer diagnosis","volume":"25","author":"Wekking","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124247_bib8","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.3390\/ijms22084159","article-title":"PET molecular imaging: a holistic review of current practice and emerging perspectives for diagnosis, therapeutic evaluation and prognosis in clinical oncology","volume":"22","author":"Duclos","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12282-015-0613-z","article-title":"Molecular imaging using PET for breast cancer","volume":"23","author":"Kurihara","year":"2016","journal-title":"Breast Cancer"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib10","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/ijms25031575","article-title":"Imaging molecular targets and metabolic pathways in breast cancer for improved clinical management: current practice and future perspectives","volume":"25","author":"Ndlovu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib12","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.3390\/jcm13123459","article-title":"PET molecular imaging in breast cancer: current applications and future perspectives","volume":"13","author":"Katal","year":"2024","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124247_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124247_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","article-title":"Advances in PET imaging of cancer","volume":"23","author":"Schwenck","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00037.2024","article-title":"Metabolic adaptations in cancer progression","volume":"106","author":"Peng-Winkler","year":"2026","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib16","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1021\/acsami.3c15686","article-title":"Advances in nanodelivery systems based on metabolism reprogramming strategies for enhanced tumor therapy","volume":"16","author":"Zhang","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib17","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/ijms26051879","article-title":"Glucose metabolism and tumor microenvironment: mechanistic insights and therapeutic implications","volume":"26","author":"Andryszkiewicz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124247_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.70008","article-title":"Aberrant energy metabolism in tumors and potential therapeutic targets","volume":"63","author":"Fan","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.biomaterials.2026.124247_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102387","article-title":"Research progress on estrogen receptor-positive\/progesterone receptor-negative breast cancer","volume":"56","author":"Lu","year":"2025","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12935-025-04149-3","article-title":"VMP1 inhibits the progression of breast cancer via regulating PI3K\/AKT and MEK\/ERK signaling pathway","volume":"26","author":"Chen","year":"2026","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1148\/radiol.2021204677","article-title":"Simultaneous FAPI PET\/MRI targeting the fibroblast-activation protein for breast cancer","volume":"302","author":"Backhaus","year":"2022","journal-title":"Radiology"},{"issue":"25","key":"10.1016\/j.biomaterials.2026.124247_bib22","first-page":"173","article-title":"18F-FDG PET\/CT for prediction of response in breast cancer","volume":"8","author":"Vorster","year":"2026","journal-title":"Semin. Nucl. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib23","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3390\/tomography8050211","article-title":"Comparison of (18)F-fluorothymidine positron emission Tomography\/Computed tomography and (18)F-fluorodeoxyglucose positron emission Tomography\/Computed tomography in patients with breast cancer","volume":"8","author":"Mori","year":"2022","journal-title":"Tomography"},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124247_bib24","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s00259-025-07186-2","article-title":"Head-to-Head comparison of [(18)F]FES and [(18)F]FDG PET\/CT in breast cancer patients: has a new era come?","volume":"52","author":"Guglielmo","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/cancers15030908","article-title":"PET\/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic Application-A literature review","volume":"15","author":"Taralli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biomaterials.2026.124247_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109454","article-title":"(18)F-HX4\/(18)F-FMISO-based micro PET for imaging of tumor hypoxia and radiotherapy-associated changes in mice","volume":"119","author":"Yu","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00432-023-05519-y","article-title":"Molecular probes targeting HER2 PET\/CT and their application in advanced breast cancer","volume":"150","author":"Gao","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib28","article-title":"PET\/CT in breast cancer","volume":"44","author":"Bastidas","year":"2025","journal-title":"Rev. Espa\u00f1ola Med. Nucl. Imagen Mol."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124247_bib29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1158\/1078-0432.CCR-25-3354","article-title":"Exploring the 89Zr\/177Lu Theranostic pairing with an extracellular matrix-targeted radiopharmaceutical against triple-negative breast cancer","volume":"32","author":"Hachey","year":"2026","journal-title":"Clin. Cancer Res."},{"issue":"27","key":"10.1016\/j.biomaterials.2026.124247_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202503117","article-title":"Chemodynamic therapy enhanced 131I-Radiotherapy for efficient inhibition on cancer growth and metastasis","volume":"21","author":"Deng","year":"2025","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","article-title":"Conventional and novel [18F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma","volume":"17","author":"Leithner","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124247_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103806","article-title":"Role of [(18)F]FDG PET\/CT in patients with invasive breast carcinoma of no special type: literature review and comparison between guidelines","volume":"78","author":"Groheux","year":"2024","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/MNM.0000000000001964","article-title":"A review of the association between baseline [18F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes","volume":"46","author":"Lenaerts","year":"2025","journal-title":"Nucl. Med. Commun."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124247_bib34","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","article-title":"Joint EANM-SNMMI guideline on the role of 2-[(18)F]FDG PET\/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA)","volume":"51","author":"Vaz","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/RLU.0000000000003502","article-title":"Impact of 18F-FDG PET, PET\/CT, and PET\/MRI on staging and management as an initial staging modality in breast cancer: a systematic review and meta-analysis","volume":"46","author":"Han","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.biomaterials.2026.124247_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.breast.2022.07.008","article-title":"Dual-phase FDG PET\/CT for predicting prognosis in operable breast cancer","volume":"65","author":"Ikejiri","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40644-022-00519-6","article-title":"Prognostic impact of (18)F-FDG PET\/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET\/CT in intermediate-risk breast cancer","volume":"23","author":"Park","year":"2023","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.biomaterials.2026.124247_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/489021","article-title":"The diagnostic value of 18F-FDG PET\/CT in association with serum tumor marker assays in breast cancer recurrence and metastasis","volume":"2015","author":"Dong","year":"2015","journal-title":"Biomed Res. Int."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00259-024-06929-x","article-title":"Pre-treatment [18F]FDG PET\/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer","volume":"52","author":"Seban","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124247_bib45","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2967\/jnumed.115.171389","article-title":"Anti-3-18F-FACBC (18F-Fluciclovine) PET\/CT of breast cancer: an exploratory study","volume":"57","author":"Tade","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"18","key":"10.1016\/j.biomaterials.2026.124247_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814124","article-title":"Evaluating [(18)F]FDG and [(18)F]FLT radiotracers as biomarkers of response for combined therapy outcome in triple-negative and estrogen-receptor-positive breast cancer models","volume":"24","author":"Rainone","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib42","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/bjc.1991.475","article-title":"Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction","volume":"64","author":"Leskinen-Kallio","year":"1991","journal-title":"Br. J. Cancer"},{"issue":"17","key":"10.1016\/j.biomaterials.2026.124247_bib49","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1158\/1078-0432.CCR-09-0666","article-title":"[11C]choline positron emission tomography in estrogen receptor-positive breast cancer","volume":"15","author":"Contractor","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124247_bib51","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1177\/0300060518773019","article-title":"PET\/CT analysis of 21 patients with breast cancer: physiological distribution of (18)F-choline and diagnostic pitfalls","volume":"46","author":"Ahmad Saad","year":"2018","journal-title":"J. Int. Med. Res."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib54","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s00259-004-1462-8","article-title":"PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study","volume":"31","author":"Smyczek-Gargya","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00259-004-1713-8","article-title":"Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer","volume":"32","author":"Sun","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2967\/jnumed.119.232363","article-title":"Breast cancer (18)F-ISO-1 uptake as a marker of proliferation status","volume":"61","author":"McDonald","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/metabo7020018","article-title":"Metabolic portraits of breast cancer by HR MAS MR spectroscopy of intact tissue samples","volume":"7","author":"Haukaas","year":"2017","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cpet.2018.02.009","article-title":"Amino acid metabolism as a target for breast cancer imaging","volume":"13","author":"Ulaner","year":"2018","journal-title":"Pet. Clin."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124247_bib44","first-page":"1472","article-title":"Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors","volume":"37","author":"Inoue","year":"1996","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biomaterials.2026.124247_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fonc.2016.00266","article-title":"Targeting phospholipid metabolism in cancer","volume":"6","author":"Cheng","year":"2016","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RLU.0000000000003987","article-title":"Histopathological features of parathyroid adenoma and 18F-Choline uptake in PET\/MR of primary hyperparathyroidism","volume":"47","author":"Liberini","year":"2022","journal-title":"Clin. Nucl. Med."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124247_bib48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/RLU.0000000000001350","article-title":"Breast cancer incidentally detected by 18F-Choline PET\/CT in a patient with recurrent prostate carcinoma","volume":"41","author":"Vadrucci","year":"2016","journal-title":"Clin. Nucl. Med."},{"issue":"16","key":"10.1016\/j.biomaterials.2026.124247_bib50","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1158\/1078-0432.CCR-10-0468","article-title":"Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab","volume":"16","author":"Kenny","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124247_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124247_bib53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.21037\/atm-23-314","article-title":"Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates","volume":"11","author":"Heater","year":"2023","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib56","first-page":"51","article-title":"(18)F-FDG and (18)F-FLT uptake profiles for breast cancer cell lines treated with targeted PI3K\/Akt\/mTOR therapies","volume":"38","author":"Dockx","year":"2023","journal-title":"Cancer Biother. Radiopharm."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","article-title":"Current medical treatment of estrogen receptor-positive breast cancer","volume":"6","author":"Lumachi","year":"2015","journal-title":"World J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124247_bib60","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1634\/theoncologist.2019-0967","article-title":"Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16\u03b1-18F-Fluoro-17\u03b2-Estradiol positron emission tomography: meta-Analysis and recommendations for integration into clinical applications","volume":"25","author":"Kurland","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2214\/AJR.22.28809","article-title":"Prospective pilot study of (18)F-Fluoroestradiol PET\/CT in patients with invasive lobular carcinomas","volume":"221","author":"Covington","year":"2023","journal-title":"AJR Am. J. Roentgenol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib62","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/RLU.0000000000005660","article-title":"Intratumoral heterogeneity of primary breast cancer on 18 F-FES PET\/CT and dbPET anticipated a heterogeneous response to chemotherapy","volume":"50","author":"Kitano","year":"2025","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib63","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.241850","article-title":"The diagnostic accuracy of (18)F-FDG PET and (18)F-FES PET for staging grade 1-2 estrogen receptor-positive breast cancer","volume":"314","author":"Knip","year":"2025","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib83","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.7150\/thno.74154","article-title":"HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib107","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2967\/jnumed.124.268564","article-title":"[99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT imaging: from preclinical to pilot clinical Study","volume":"66","author":"Sun","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"22","key":"10.1016\/j.biomaterials.2026.124247_bib127","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.7150\/thno.34857","article-title":"CMKLR1-targeting peptide tracers for PET\/MR imaging of breast cancer","volume":"9","author":"Erdmann","year":"2019","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib64","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.semnuclmed.2022.03.002","article-title":"16\u03b1-18F-fluoro-17\u03b2-Fluoroestradiol (FES): clinical applications for patients with breast cancer","volume":"52","author":"Ulaner","year":"2022","journal-title":"Semin. Nucl. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib65","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1470-2045(18)30936-7","article-title":"Diagnostic accuracy and safety of 16\u03b1-[(18)F]fluoro-17\u03b2-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study","volume":"20","author":"Chae","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib66","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00259-024-07058-1","article-title":"Predictive and prognostic value of (18)F-FES PET\/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4\/6 inhibitors","volume":"52","author":"Jeong","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124247_bib67","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2967\/jnumed.117.198846","article-title":"(18)F-Fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients","volume":"59","author":"Nienhuis","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biomaterials.2026.124247_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nucmedbio.2018.01.003","article-title":"(18)F-labeled estradiol derivative for targeting estrogen receptor-expressing breast cancer","volume":"59","author":"Xu","year":"2018","journal-title":"Nucl. Med. Biol."},{"issue":"41","key":"10.1016\/j.biomaterials.2026.124247_bib69","doi-asserted-by":"crossref","first-page":"13998","DOI":"10.1021\/acs.analchem.1c03616","article-title":"Radioiodinated 4-(p-Iodophenyl) butanoic acid-modified estradiol derivative for ER targeting SPECT imaging","volume":"93","author":"Xu","year":"2021","journal-title":"Anal. Chem."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib73","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2967\/jnumed.120.249508","article-title":"Longitudinal molecular imaging of progesterone receptor reveals early differential response to endocrine therapy in breast cancer with an activating ESR1 mutation","volume":"62","author":"Kumar","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib74","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1021\/bc1001054","article-title":"Development of [F-18]fluorine-substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography","volume":"21","author":"Lee","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124247_bib79","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2967\/jnumed.115.172031","article-title":"Detection of HER2-Positive metastases in patients with HER2-Negative primary breast cancer using 89Zr-Trastuzumab PET\/CT","volume":"57","author":"Ulaner","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib80","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/MNM.0b013e328365d99b","article-title":"Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer","volume":"34","author":"Beylergil","year":"2013","journal-title":"Nucl. Med. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib81","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2967\/jnumed.117.193888","article-title":"Tumor uptake of (64)Cu-DOTA-Trastuzumab in patients with metastatic breast cancer","volume":"59","author":"Mortimer","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124247_bib86","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2967\/jnumed.122.265364","article-title":"Human epidermal growth factor receptor 2-Targeting [(68)Ga]Ga-ABY-025 PET\/CT predicts early metabolic response in metastatic breast cancer","volume":"64","author":"Alhuseinalkhudhur","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib87","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232209","article-title":"Comparison of an affibody-based molecular probe and (18)F-FDG for detecting HER2-Positive breast cancer at PET\/CT","volume":"311","author":"Guo","year":"2024","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib89","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1097\/RLU.0000000000005208","article-title":"Targeting breast cancer using 177 Lu-Labeled trastuzumab and trastuzumab fragment : First-in-Human clinical experience","volume":"49","author":"Rathore","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124247_bib91","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.125.269601","article-title":"225Ac \u03b1-Pretargeted radioimmunotherapy of human epidermal growth factor receptor 2-Expressing breast cancer","volume":"66","author":"Rinne","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib92","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-020-01270-1","article-title":"Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer","volume":"22","author":"McKnight","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib94","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00259-020-04978-6","article-title":"Development of [(89)Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer","volume":"48","author":"Cavaliere","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109750","article-title":"Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and\/or EGFR","volume":"27","author":"Kwon","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41181-023-00235-x","article-title":"Preclinical evaluation of the theranostic potential of (89)Zr\/(177)Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model","volume":"9","author":"Wu","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib110","first-page":"1586","article-title":"ImmunoPET of the differential expression of CD146 in breast cancer","volume":"11","author":"Ferreira","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124247_bib111","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acs.bioconjchem.0c00649","article-title":"ImmunoPET of CD146 in orthotopic and metastatic breast cancer models","volume":"32","author":"Li","year":"2021","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib115","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s11307-016-0953-x","article-title":"Preclinical evaluation of an Anti-Nectin-4 ImmunoPET reagent in tumor-bearing mice and biodistribution studies in cynomolgus monkeys","volume":"18","author":"Campbell","year":"2016","journal-title":"Mol. Imag. Biol."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168248","article-title":"68Ga-TRAP-(RGD)3 hybrid imaging for the in vivo monitoring of \u03b1v\u00df3-Integrin expression as biomarker of anti-angiogenic therapy effects in experimental breast cancer","volume":"11","author":"Kazmierczak","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib121","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2967\/jnumed.107.045526","article-title":"Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET","volume":"49","author":"Beer","year":"2008","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib124","first-page":"152","article-title":"First-In-Human Study demonstrating tumor-angiogenesis by PET\/CT imaging with (68)Ga-NODAGA-THERANOST, a high-affinity peptidomimetic for \u03b1v\u03b23 Integrin receptor targeting","volume":"30","author":"Baum","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib130","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00259-015-3232-1","article-title":"Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET\/CT","volume":"43","author":"Maina","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib132","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7150\/thno.22601","article-title":"(68)Ga-BBN-RGD PET\/CT for GRPR and Integrin \u03b1(v)\u03b2(3) imaging in patients with breast cancer","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib134","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-018-0442-0","article-title":"PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma","volume":"8","author":"Vag","year":"2018","journal-title":"EJNMMI Res."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124247_bib138","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00259-015-3038-1","article-title":"ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment","volume":"42","author":"Shi","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.115.154849","article-title":"Quantitative PET imaging of tissue factor expression using 18F-Labeled active site-inhibited factor VII","volume":"57","author":"Nielsen","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biomaterials.2026.124247_bib146","article-title":"Synthesis and characterization of (64)Cu-labeled Geldanamycin derivative for imaging HSP90 expression in breast cancer","volume":"136\u2013137","author":"Li","year":"2024","journal-title":"Nucl. Med. Biol."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124247_bib149","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.7150\/ijms.35452","article-title":"Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer","volume":"16","author":"Stergiou","year":"2019","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41181-021-00127-y","article-title":"Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma","volume":"6","author":"Al Jammaz","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib153","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/RLU.0000000000002821","article-title":"18F-PSMA 1007 uptake in brain metastases from breast cancer","volume":"45","author":"Marafi","year":"2020","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib155","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-018-4717-y","article-title":"Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy","volume":"169","author":"Tolkach","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib157","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13058-024-01787-9","article-title":"The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer","volume":"26","author":"Heesch","year":"2024","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib166","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12951-022-01272-5","article-title":"Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents","volume":"20","author":"Hagemans","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1124\/pharmrev.122.000665","article-title":"Newly developed targeted therapies against the androgen receptor in triple-negative breast cancer: a review","volume":"75","author":"Choupani","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biomaterials.2026.124247_bib71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-031-70875-6_15","article-title":"Hormone signaling in breast development and cancer","volume":"1464","author":"Agnoletto","year":"2025","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib72","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41467-020-20814-9","article-title":"Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy","volume":"12","author":"Dehdashti","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib76","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib77","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/jcp.29216","article-title":"Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy","volume":"235","author":"Derakhshani","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib78","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2967\/jnumed.119.228858","article-title":"Recent advances in imaging steroid hormone receptors in breast cancer","volume":"61","author":"Kumar","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2967\/jnumed.118.210294","article-title":"Development of (64)Cu-NOTA-Trastuzumab for HER2 targeting: a radiopharmaceutical with improved pharmacokinetics for human studies","volume":"60","author":"Woo","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib84","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7150\/thno.13502","article-title":"Measuring HER2-Receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET\/CT","volume":"6","author":"S\u00f6rensen","year":"2016","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib85","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.113.131243","article-title":"First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule","volume":"55","author":"S\u00f6rensen","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib88","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/ph17060732","article-title":"In vitro assessment of 177Lu-Labeled trastuzumab-targeted mesoporous Carbon@Silica nanostructure for the treatment of HER2-Positive breast cancer","volume":"17","author":"Tun\u00e7el","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib90","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1021\/acs.molpharmaceut.4c01071","article-title":"Preclinical comparison of [111In]In- and [225Ac]Ac-DOTA-Trastuzumab IgG, F(ab')2 and Fab for theranostic SPECT\/CT imaging and \u03b1-Particle radioimmunotherapy of HER2-Positive human breast cancer","volume":"22","author":"Kondo","year":"2025","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152585","article-title":"The Association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer","volume":"11","author":"Chae","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib95","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","article-title":"A novel anti-HER2\/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs","volume":"43","author":"Huang","year":"2025","journal-title":"Invest. N. Drugs"},{"issue":"13","key":"10.1016\/j.biomaterials.2026.124247_bib96","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"APHINITY Steering committee and investigators. Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer in the APHINITY trial: 6 years' Follow-Up","volume":"39","author":"Piccart","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib97","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-021-01323-y","article-title":"Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer","volume":"125","author":"Bines","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124247_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2023.108383","article-title":"Comparison of three (18)F-labeled 2-nitroimidazoles for imaging hypoxia in breast cancer xenografts: [(18)F]FBNA, [(18)F]FAZA and [(18)F]FMISO","author":"Dos Santos","year":"2023","journal-title":"Nucl. Med. Biol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib100","first-page":"309","article-title":"Trop2: a possible therapeutic target for late stage epithelial carcinomas","volume":"1796","author":"Cubas","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096993","article-title":"Trop-2 is a determinant of breast cancer survival","volume":"9","author":"Ambrogi","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib102","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41523-021-00341-6","article-title":"Oncogene-mediated metabolic gene signature predicts breast cancer outcome","volume":"7","author":"Aslan","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"16","key":"10.1016\/j.biomaterials.2026.124247_bib103","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"ASCENT clinical trial investigators, Sacituzumab Govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib104","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1634\/theoncologist.12-12-1379","article-title":"Immuno-PET: a navigator in monoclonal antibody development and applications","volume":"12","author":"van Dongen","year":"2007","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2967\/jnumed.121.262290","article-title":"An (89)Zr-Labeled PSMA tracer for PET\/CT imaging of prostate cancer patients","volume":"63","author":"Dietlein","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10050134","article-title":"The prevalence of CD146 expression in breast cancer subtypes and its relation to outcome","volume":"10","author":"de Kruijff","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib109","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1073\/pnas.1111053108","article-title":"CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer","volume":"109","author":"Zeng","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biomaterials.2026.124247_bib112","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4614-8090-7_5","article-title":"Roles of nectins and nectin-like molecules in the nervous system","volume":"8","author":"Mori","year":"2014","journal-title":"Adv Neurobiol"},{"issue":"16","key":"10.1016\/j.biomaterials.2026.124247_bib113","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124247_bib114","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124247_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.579068","article-title":"The biological functions and clinical applications of integrins in cancers","volume":"11","author":"Su","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"15","key":"10.1016\/j.biomaterials.2026.124247_bib117","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.7150\/jca.44313","article-title":"Angiogenesis in breast cancer progression, diagnosis, and treatment","volume":"11","author":"Madu","year":"2020","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib118","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41388-020-01588-2","article-title":"Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance","volume":"40","author":"Yousefi","year":"2021","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib119","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1007\/s00259-021-05352-w","article-title":"Iagaru A; Young Italian association of Nuclear Medicine (AIMN) group, unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas","volume":"48","author":"Laudicella","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib122","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/RLU.0000000000005963","article-title":"Triple negative breast cancer and 68 Ga-Trivehexin : a glance of hope","volume":"51","author":"Marafi","year":"2026","journal-title":"Clin. Nucl. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib123","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1148\/radiol.14140028","article-title":"(18)F-FPPRGD2 PET\/CT: pilot phase evaluation of breast cancer patients","volume":"273","author":"Iagaru","year":"2014","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib125","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41573-025-01139-y","article-title":"GPCR drug discovery: new agents, targets and indications","volume":"24","author":"Lorente","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib126","article-title":"The concentration of CMKLR1 expression on clinicopathological parameters of colorectal cancer: a preliminary Study","volume":"57","author":"Kiczmer","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"30","key":"10.1016\/j.biomaterials.2026.124247_bib128","doi-asserted-by":"crossref","first-page":"12462","DOI":"10.1073\/pnas.0705347104","article-title":"[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues","volume":"104","author":"Prasanphanich","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124247_bib129","first-page":"1390","article-title":"microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts","volume":"45","author":"Chen","year":"2004","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib131","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/bc9000245","article-title":"(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer","volume":"20","author":"Liu","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.biomaterials.2026.124247_bib133","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3389\/fonc.2019.00770","article-title":"CXCR4-Directed imaging in solid tumors","volume":"9","author":"Werner","year":"2019","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib135","doi-asserted-by":"crossref","first-page":"908","DOI":"10.5306\/wjco.v5.i5.908","article-title":"Breast cancer phenotypes regulated by tissue factor-factor VII pathway: possible therapeutic targets","volume":"5","author":"Koizume","year":"2014","journal-title":"World J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124247_bib136","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-04-0866","article-title":"Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma","volume":"11","author":"Nitori","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124247_bib137","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.112.105460","article-title":"Immuno-PET of tissue factor in pancreatic cancer","volume":"53","author":"Hong","year":"2012","journal-title":"J. Nucl. Med."},{"issue":"18","key":"10.1016\/j.biomaterials.2026.124247_bib139","doi-asserted-by":"crossref","first-page":"11863","DOI":"10.1074\/jbc.272.18.11863","article-title":"Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor","volume":"272","author":"Sorensen","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib141","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.2967\/jnumed.122.264068","article-title":"First-in-Humans PET imaging of tissue factor in patients with primary and metastatic cancers using (18)F-labeled active-site inhibited factor VII ((18)F-ASIS): potential as companion diagnostic","volume":"63","author":"Loft","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib142","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/bcr1201","article-title":"Imaging in breast cancer: single-photon computed tomography and positron-emission tomography","volume":"7","author":"B\u00e9nard","year":"2005","journal-title":"Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124247_bib143","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib144","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2214\/ajr.183.2.1830479","article-title":"Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer","volume":"183","author":"Eubank","year":"2004","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-006-9435-1","article-title":"Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)","volume":"105","author":"Specht","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124247_bib147","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/onc.2012.158","article-title":"MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches","volume":"32","author":"Kufe","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.biomaterials.2026.124247_bib148","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-018-0013-x","article-title":"Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer","volume":"3","author":"Hiraki","year":"2018","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124247_bib151","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.nucmedbio.2016.03.006","article-title":"Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: a potential candidate for the targeting of breast carcinoma","volume":"43","author":"Okarvi","year":"2016","journal-title":"Nucl. Med. Biol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib152","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.117.203570","article-title":"Imaging of nonprostate cancers using PSMA-Targeted radiotracers: Rationale, Current State of the field, and a call to arms","volume":"59","author":"Salas Fragomeni","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib154","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1097\/RLU.0000000000003336","article-title":"Recurrent brain metastasis of triple negative breast cancer with high uptake in 68Ga-PSMA-11 PET\/CT","volume":"46","author":"Arslan","year":"2021","journal-title":"Clin. Nucl. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib156","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clgc.2018.11.020","article-title":"Male breast cancer detected by (68)Ga-PSMA-11 PET\/CT in a patient with prostate cancer with pelvic lymph Node metastasis","volume":"17","author":"Polverari","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib158","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.biomaterials.2026.124247_bib159","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1016\/j.ejca.2012.05.001","article-title":"Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis","volume":"48","author":"Chalkidou","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124247_bib160","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.4049\/jimmunol.1401572","article-title":"The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity","volume":"193","author":"Ostrand-Rosenberg","year":"2014","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib161","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"26","key":"10.1016\/j.biomaterials.2026.124247_bib162","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib163","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/2326-6066.CIR-13-0042","article-title":"Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma","volume":"1","author":"Joseph","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib164","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"26","key":"10.1016\/j.biomaterials.2026.124247_bib165","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16040532","article-title":"(68)Ga-DOTA-D-Alanine-BoroPro radiotracer for imaging of the fibroblast activation protein in malignant and non-malignant diseases","volume":"16","author":"Trujillo-Ben\u00edtez","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib168","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124247_bib169","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","article-title":"(68)Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: a comparative pilot study with the (18)F-FDG PET\/CT","volume":"35","author":"K\u00f6mek","year":"2021","journal-title":"Ann. Nucl. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib170","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-021-05442-9","article-title":"(68)Ga-FAPI-04 vs. (18)F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer","volume":"49","author":"Ding","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib171","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.123.266798","article-title":"(68)Ga-FAPI PET\/CT as an alternative to (18)F-FDG PET\/CT in the imaging of invasive lobular breast carcinoma","volume":"65","author":"Sahin","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124247_bib179","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2967\/jnumed.120.252064","article-title":"Sentinel lymph Node Biopsy in breast cancer with (99m)Tc-Tilmanocept: a multicenter Study on real-life use of a novel tracer","volume":"62","author":"Vidal-Sicart","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib192","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00259-021-05544-4","article-title":"Eribulin improves tumor oxygenation demonstrated by (18)F-DiFA hypoxia imaging, leading to radio-sensitization in human cancer xenograft models","volume":"49","author":"Bo","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib172","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1021\/acs.molpharmaceut.3c00886","article-title":"Synthesis and preliminary Study of (99m)Tc-Labeled HYNIC-FAPi for imaging of fibroblast activation proteins in tumors","volume":"21","author":"Ma","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2026.124247_bib173","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1007\/s00259-024-06704-y","article-title":"Targeting CXCR4\/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer","volume":"51","author":"Bao","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib174","first-page":"1917","article-title":"Feasibility, tolerability, and preliminary clinical response of fractionated radiopharmaceutical therapy with 213Bi-FAPI-46: pilot experience in patients with End-Stage, progressive metastatic tumors","volume":"65","author":"Helisch","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124247_bib175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: First-in-Humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biomaterials.2026.124247_bib176","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1007\/s00259-024-06817-4","article-title":"The complete metabolic\/molecular response to chemotherapy combined with [177Lu]Lu-FAP-2286 in metastatic breast cancer","volume":"51","author":"Banihashemian","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.biomaterials.2026.124247_bib177","article-title":"Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET\/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy","author":"Liu","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"16","key":"10.1016\/j.biomaterials.2026.124247_bib180","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1158\/0008-5472.CAN-11-2994","article-title":"Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages","volume":"72","author":"Movahedi","year":"2012","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124247_bib183","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2967\/jnumed.112.117218","article-title":"89Zr-bevacizumab PET imaging in primary breast cancer","volume":"54","author":"Gaykema","year":"2013","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib186","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1021\/acs.molpharmaceut.4c00983","article-title":"Immuno-PET imaging of CD93 expression with (64)Cu-Radiolabeled NOTA-mCD93 ([(64)Cu]Cu-NOTA-mCD93) and insulin-like growth factor binding protein 7 ([(64)Cu]Cu-NOTA-IGFBP7)","volume":"21","author":"Li","year":"2024","journal-title":"Mol. Pharm."},{"issue":"24","key":"10.1016\/j.biomaterials.2026.124247_bib190","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1007\/s00018-007-7390-6","article-title":"Hypoxia and breast cancer: prognostic and therapeutic implications","volume":"64","author":"Lundgren","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124247_bib193","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/open.202100044","article-title":"Cellular uptake of the ATSM-Cu(II) complex under hypoxic conditions","volume":"10","author":"Walke","year":"2021","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.biomaterials.2026.124247_bib197","article-title":"Target engagement of an anti-MT1-MMP antibody for triple-negative breast cancer PET imaging and beta therapy","volume":"136\u2013137","author":"Magro","year":"2024","journal-title":"Nucl. Med. Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib178","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001341","article-title":"Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer","volume":"9","author":"Li","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib181","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124247_bib182","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115544","article-title":"Molecular imaging of angiogenesis in oncology: current preclinical and clinical status","volume":"22","author":"Florea","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124247_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2021.05.006","article-title":"The C-type lectin CD93 controls endothelial cell migration via activation of the Rho family of small GTPases","volume":"99","author":"Barbera","year":"2021","journal-title":"Matrix Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12935-023-03044-z","article-title":"Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization","volume":"23","author":"Li","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"24","key":"10.1016\/j.biomaterials.2026.124247_bib187","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202300530","article-title":"Strategic design of conquering hypoxia in tumor for advanced photodynamic therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.biomaterials.2026.124247_bib188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2024.01.010","article-title":"Current advances in modulating tumor hypoxia for enhanced therapeutic efficacy","volume":"176","author":"Liu","year":"2024","journal-title":"Acta Biomater."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124247_bib189","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/cells13121048","article-title":"Affinity of PET-MRI tracers for hypoxic cells in breast cancer: a systematic review","volume":"13","author":"Costin","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124247_bib191","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11307-018-1214-y","article-title":"A novel PET probe \"[(18)F]DiFA\" accumulates in hypoxic Region via glutathione conjugation following reductive metabolism","volume":"21","author":"Shimizu","year":"2019","journal-title":"Mol. Imag. Biol."},{"issue":"13","key":"10.1016\/j.biomaterials.2026.124247_bib194","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137226","article-title":"Breast cancer: extracellular matrix and microbiome interactions","volume":"25","author":"Herrera-Quintana","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124247_bib195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.semcancer.2019.09.004","article-title":"Emerging roles of ECM remodeling processes in cancer","volume":"62","author":"Mohan","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124247_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/ph12020077","article-title":"The expanding role of MT1-MMP in cancer progression","volume":"12","author":"Knapinska","year":"2019","journal-title":"Pharmaceuticals"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226002711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226002711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:29:25Z","timestamp":1794562165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226002711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":197,"alternative-id":["S0142961226002711"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124247","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in multi-dimensional targeting probes for precision medicine of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124247"}}